Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by YukonJezza on Jan 07, 2021 9:00pm

Don Haut

well after Don Haut coming on board I bought some more ATE. Don Haut is no small potato.
Comment by Ryeman40 on Jan 07, 2021 9:40pm
Interestingly Don Haut also worked at Monsato albeit at a early age. Monsato was also bought by Bayer for 66 billion in 2018. 
Comment by crow27 on Jan 07, 2021 10:47pm
He knows all the right people at Bayer. Connecting the dots does not seem that hard to do. ATE/ Don Haut/ Bayer.  This guy is the deal maker for Bayer and now he is on ATE''s partnering advisory team. HELLO!!!!!! This is the beginning of some real traction for the stock. Hopefully everyone loaded up in that $3.40 - $3.50 range. The train is leaving the station folks.
Comment by TriumphSpitSix on Jan 08, 2021 1:10am
Dr. Haut commented, “Antibe’s platform promises a major advance in the treatment of pain and inflammation-based disease. This area is overdue for disruption and represents a massive commercial opportunity. I’m excited to put my shoulder to the wheel to help Antibe fully capture the value of its pipeline as it enters late-stage development.” Seems the proverbial writing is on the wall... Full drug ...more  
Comment by 3burtc on Jan 08, 2021 2:14am
This isn't your everyday, run of the mill nsaid. This drug is a game changer. Otezla sod for 8 times revenue at 15 billion dollars! 346 revenue projected to be atleast double that. My guess is discussions with multiple companies are taking place as we speak.
Comment by Doccole on Jan 08, 2021 6:37am
I believe it was highly important to get the news out before JP Morgan.  I also think it's interesting to see that AskBio IPO was scrapped because BigPharma jumped in.  BigPharma really waits to the last moment.   the hydrogen sulfide platform offers so many opportunities for future drugs targeting inflammation.  How much will OTENA fetch? Exciting times!
Comment by Forestview on Jan 08, 2021 8:45am
Good point 3B, but if 346 has no revenue, and still needs to go through Phase 3, what's the impact to a potential acquisition?
Comment by 3burtc on Jan 08, 2021 8:52am
Of course it's not the same as an approved drug. But let's face it, it will be approved. The fact the they are willing to move the IP out of Holdings company will give nothing but confidence to shareholders and big pharma.
Comment by bringon10bagger on Jan 09, 2021 11:55am
Dr. Haut don't beat the bushes, apparently was at AskBio only since March'20 and inked the $4B deal, $2B upfront + $2B in milestone payments with Bayer by October, at this point knowing Haut is involved Bayer will just ante up to ATE's ask....LOL.....expecting a similar arrangement with ATE, interesting to know ATE's position and to the extent of the offering entire H2S platform or ...more  
Comment by bringon10bagger on Jan 09, 2021 12:02pm
Comments by Bayer after AsBio aquisition.....sounds like ATE to the "T" “We were looking for a company with a very strong technology platform and broad intellectual property (IP) around it,” she said. “We wanted a company that had proven success, and with manufacturing capability.” We feel that with AskBio, we have acquired an IND-machine. We think it’s an extremely valuable ...more  
Comment by Pragmatist on Jan 09, 2021 1:06pm
That is a great observation 10Bagger!  I really like the IND-machine part. If ATE is talking with Bayer, then it might explain why ATE now wants to consolidate its IP suite with AHI, when it was perfectly happy with the existing arrangement for past partnering deals.  
Comment by themagicbox on Jan 08, 2021 9:36am
Youre right. Even the economic studies commisioned by ATE had similiar (and very conservative) first year estimates. Normally, its the analysts working for instos that do this. But ATE did the work for them, through a third party, to speed up their investing process. Dan and JLW are looking for an exit strategy, so JLW can get his emeritus on, and Dan can retire on his farm haha.  
Comment by 3burtc on Jan 08, 2021 9:42am
Just my opinion but i think the FDA fast tracks 346. After all, they've been pounding the table about having these issues resolved.
Comment by themagicbox on Jan 08, 2021 9:48am
I think that could happen for Otena/346 if it shows some indication for COVID related complications.
Comment by Pandora on Jan 08, 2021 7:35pm
Just an observation but it seems that Stockhouse is not receiving the Antibe news releases over the past two months. The last item shown under the "news" link above is from November 10. According to the Antibe web site there have been 5 additional releases in 2020 and 1 release thus far in 2021 i.e. the one concerning Don Haut. Not sure why they are missing the link but it seems to ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities